Idroxioleic acid(Synonyms: (R)-2-Hydroxyoleic acid; (R)-2-OHOA)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Idroxioleic acid (Synonyms: (R)-2-Hydroxyoleic acid; (R)-2-OHOA)

Idroxoleic acid ((R)-2-Hydroxyoleic acid; (R)-2-OHOA) 是 (Rac)-Idroxoleic acid 的 R 对映异构体,是一种口服活性脂肪酸,可调节膜的脂质组成和结构。Idroxoleic acid 具有抗肿瘤活性。

Idroxioleic acid(Synonyms: (R)-2-Hydroxyoleic acid;  (R)-2-OHOA)

Idroxioleic acid Chemical Structure

CAS No. : 182370-45-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Idroxioleic acid ((R)-2-Hydroxyoleic acid; (R)-2-OHOA), the R enantiomer of (Rac)-Idroxioleic acid, is an orally active fatty acid that modulates the lipid composition and structure of the membranes. Idroxioleic acid has antitumor activities[1].

体外研究
(In Vitro)

Idroxioleic acid ((R)-2-Hydroxyoleic acid; (R)-2-OHOA) inhibited the growth of A549, lung adenocarcinoma cell line with an IC50 of 252 μM[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Idroxioleic acid ((R)-2-Hydroxyoleic acid; (R)-2-OHOA; 400 mg/kg; p.o.; daily; for 21 days) causes a reduction in tumor volume of about 20-25% after 21 days[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male NUDE (Swiss) Crl:NU(Ico)-Foxn1nu mice (5 weeks old, 30-35 g) injected with A549 human lung cancer cells[1]
Dosage: 400 mg/kg
Administration: p.o.; daily; for 21 days
Result: Caused a reduction in tumor volume of about 20-25% after 21 days.

分子量

298.46

Formula

C18H34O3

CAS 号

182370-45-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Stefano Piotto, et al. Differential effect of 2-hydroxyoleic acid enantiomers on protein (sphingomyelin synthase) and lipid (membrane) targets. Biochim Biophys Acta. 2014 Jun;1838(6):1628-37.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务